Paul Kudelko, DO
Cardiovascular Disease · Hendersonville, TNNPI 1225027014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,659 of the $155,631 with a category attached, or 83.3%. Novo Nordisk accounts for 94.3% of it on its own, with 36 other manufacturers making up the rest. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $338.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$147K
- Johnson & Johnson$2K
- Amgen$1K
- Inari Medical, Inc.$886
- Pfizer$439
- Shockwave Medical, Inc$438
- plus $4K from 31 others
What the payments were for
- Speaking & faculty fees$129,65983%
- Travel & lodging$14,0699%
- Food & beverage$11,8688%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 103 | $146,806 |
| Johnson & Johnson | 77 | $1,756 |
| Amgen | 46 | $1,327 |
| Inari Medical, Inc. | 6 | $886 |
| Pfizer | 31 | $439 |
| Shockwave Medical, Inc | 4 | $438 |
| Abbott | 3 | $421 |
| Novartis | 28 | $409 |
| Boston Scientific | 18 | $405 |
| E.r. Squibb & Sons, L.L.C. | 28 | $380 |
| AstraZeneca | 19 | $295 |
| Boehringer Ingelheim | 13 | $275 |
| Actelion Pharmaceuticals US, Inc. | 12 | $228 |
| Bayer | 6 | $227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $165 |
| Inquis Medical, Inc. | 1 | $158 |
| Merck | 6 | $129 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $118 |
| Baxter Healthcare | 5 | $94 |
| Amarin Pharma, Inc. | 5 | $84 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $54 |
| Astellas Pharma US Inc | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Lilly USA, LLC | 2 | $45 |
| Lundbeck LLC | 3 | $41 |
| Abiomed | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Portola Pharmaceuticals, LLC | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Acist Medical Systems, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Surmodics, Inc. | 1 | $23 |
| Celonova Biosciences, Inc. | 1 | $20 |
| Cardiac Dimensions, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Cashflow Solutions, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,631 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 270 | $339,419 |
| XareltoRivaroxaban | 195 | $206,602 |
| OzempicSemaglutide | 93 | $101,791 |
| Repatha SureclickEvolocumab | 68 | $55,703 |
| JardianceEmpagliflozin | 49 | $55,562 |
| WegovySemaglutide | 15 | $23,314 |
| MounjaroTirzepatide | 18 | $23,056 |
| EntrestoSacubitril/Valsartan | 23 | $22,349 |
| TrulicityDulaglutide | 15 | $14,635 |
| BrilintaTicagrelor | 13 | $8,428 |
| Atorvastatin Calcium | 616 | $8,182 |
| Amiodarone Hcl | 171 | $5,690 |
| ClopidogrelClopidogrel Bisulfate | 522 | $5,687 |
| Flecainide Acetate | 119 | $5,524 |
| Carvedilol | 662 | $5,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $439 | $339,419270 claims |
| Johnson & JohnsonXarelto | $1,756 | $206,602195 claims |
| Novo NordiskOzempic, Wegovy | $146,806 | $125,105108 claims |
| Boehringer IngelheimJardiance | $275 | $55,56249 claims |
| Lilly USA, LLCMounjaro, Trulicity | $45 | $37,69133 claims |
| NovartisEntresto | $409 | $22,34923 claims |
| AstraZenecaBrilinta | $295 | $8,42813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Hendersonville
- Jung LeeHendersonville$45K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.